Previous 10 | Next 10 |
Total Third-Quarter Revenues of $164.0 Million Third-Quarter Diluted EPS of ($1.55) and Adjusted EPS of ($0.08) SALT LAKE CITY, May 05, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecula...
SALT LAKE CITY, April 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal third-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m. EDT on Tue...
There are a few stocks in my investment club's portfolio that seem, quite simply, to never catch a break. Of course, it begs the question of whether we should be investing in companies that need to catch a break. Myriad Genetics (MYGN) is one of those investments. Our investment thesis in My...
SALT LAKE CITY, April 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the publication of a meta-analysis of four clinical trials demonst...
Myriad Genetics (NASDAQ: MYGN ) has withdrawn its 2020 guidance after a difficult March. More news on: Myriad Genetics, Inc., Centene Corporation, Roche Holding Ltd ADR, Healthcare stocks news, Read more ...
SALT LAKE CITY, April 08, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today that due to the impact of the global COVID-19 pandemic, the company is withdrawing its fiscal year 2020 financial guidance. “Prior to m...
SALT LAKE CITY, April 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has received reimbursement and launched the BRACAnalysis ® Diagnostic System (i.e., “BRACAnalysis”) in J...
SALT LAKE CITY, March 30, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced it has submitted a supplementary application with the Japanese Ministry of Health Labour and Welfare for its BRACAnalysis ® ...
S. Louise Phanstiel Appointed Chair of the Board of Directors; John T. Henderson, M.D., to Remain on the Board SALT LAKE CITY, March 23, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced ...
Investors continue to assess the economic fallout from the coronavirus pandemic. As the stock market whips around in search of a bottom, genetic testing stocks are being tossed around -- partly due to broader economic concerns, and partly due to concerns that genetic testing services are likely ...
News, Short Squeeze, Breakout and More Instantly...
2024-04-23 07:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest GeneSight Mental Health Monitor, a ...
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study 1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 micr...